In 2014, Calithera and Mars Symbiosciences signed an exclusive global license agreement that granted Calithera rights to research, develop, and commercialize Symbioscience’s portfolio of arginase inhibitors. In July 2016, an Investigational New Drug (IND) application for CB-1158 was accepted by the FDA, and the first patient was dosed in the Phase 1 study in September 2016. In January 2017, Calithera and Incyte announced a global collaboration to develop and commercialize arginase inhibitors, including CB-1158, in hematology and oncology indications.